Search

1 to 10 of 169
Sort by

Library Entry
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article where researchers explained how vaccination were combined with single low-dose chemotherapy as precondition to polarize immunosuppressive cells and thus modulate the immune system. Authors: Claudia Maletzki , ...



Library Entry
Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report about the first case of myocarditis in a patient with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of nivolumab, an anti-programmed cell death protein 1 antibody, and PROSTVAC, a...


Library Entry
Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article that discusses ways to improve cancer vaccination by further assessing the immunological properties of novel TLR2-L Amplivant (AV). Authors: Gijs G. Zom , Marian M. J. H. P. Willems , Selina Khan , Tetje C....


Library Entry
Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Published in the Journal for ImmunoTherapy of Cancer (JITC), is an update on long-term survival results from two single-arm, phase II adjuvant trials (Trial 3 and Trial 5) with the focus on treatment beyond recurrence of the disease. Authors: Jacek Mackiewicz , Tomasz Burzykowski , Dariusz...


Library Entry
Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report of a patient with concomitant primary cutaneous ALCL and metastatic melanoma, progressing on anti-programmed death (PD)-1 therapy, who developed Kaposi’s varicelliform eruption after receiving the first dose of...


Library Entry
IMMUNOTHERAPY: The Path to a Cancer Cure (For Clinicians) - Chinese

Created by Dr. Samir N. Khleif at the Georgia Cancer Center at Augusta University, in partnership with the Society for Immunotherapy of Cancer (SITC) and Cancer Support Community, IMMUNOTHERAPY: The Path to a Cancer Cure explains the interplay between the immune system and cancer; mechanisms...

IMMUNOTHERAPY - The Path to a Cancer Cure! (for Clinicians) Chinese.mp4


Library Entry
IMMUNOTHERAPY: The Path to a Cancer Cure (For Patients) - Spanish

Created by Dr. Samir N. Khleif, a nationally recognized medical oncologist/scientist, immune therapy specialist and member of the SITC Board of Directors, and in partnership with the Society for Immunotherapy of Cancer (SITC) and Cancer Support Community, IMMUNOTHERAPY: The Path to a Cancer Cure...

IMMUNOTHERAPY - The Path to a Cancer Cure! (for Patients) Spanish.mp4


Library Entry
IMMUNOTHERAPY: The Path to a Cancer Cure (For Patients) - Chinese

Created by Dr. Samir N. Khleif, a nationally recognized medical oncologist/scientist, immune therapy specialist and member of the SITC Board of Directors, and in partnership with the Society for Immunotherapy of Cancer (SITC) and Cancer Support Community, IMMUNOTHERAPY: The Path to a Cancer Cure...

IMMUNOTHERAPY - The Path to a Cancer Cure! (for Patients) Chinese.mp4


Library Entry
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article which proposed that the addition of anti-CSF-1R antibody to the combination of GVAX therapy and anti-PD-1 antibody can improve the survival outcome of PDAC by further altering the myeloid population and creating...